10-K: United-Guardian Reports 13% Sales Drop in 2025, Pharma Sales Up

United-Guardian, Inc. reported a 13% decrease in total sales for 2025, driven by a significant decline in cosmetic ingredient sales, while pharmaceutical and medical lubricant sales saw growth.

Summary

• Total sales decreased by 13% to $10.55 million in 2025 from $12.18 million in 2024.
• Net income fell by 35.2% to $2.11 million in 2025 from $3.25 million in 2024.
• Cosmetic ingredient sales plummeted by 45% to $3.01 million, primarily due to a 54% decrease in sales to the largest distributor, ASI, attributed to decreased demand in Asia and overstocking.
• Pharmaceutical net sales increased by 15% to $5.43 million, driven by increased orders and reduced Medicare rebates due to a new program phase-in.
• Medical lubricant sales grew by 4% to $2.11 million, largely due to increased demand from two major customers in China.
• Gross profit margin decreased to 49% in 2025 from 53% in 2024, mainly due to the shift in product mix towards lower-margin pharmaceutical products and higher per-unit overhead.
• Operating expenses increased by 3% to $2.43 million, influenced by higher payroll and consulting fees.
• R&D expenses rose slightly by 2% to $463,644, with further increases anticipated in 2026 to support growth initiatives.
• Working capital decreased to $10.53 million from $10.75 million, while the current ratio improved to 7.3:1 from 6.6:1.
• Cash from operations decreased to $1.97 million from $3.47 million, primarily due to lower net income and changes in working capital.
• No sales were recorded for the new Natrajel sexual wellness ingredients line in 2025, but manufacturing and distribution are ready for 2026.
• A settlement with the Renacidin contract manufacturer for a 2023-2024 supply disruption will result in $300,000 worth of product supplied at no cost in March 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with significant declines in overall sales and net income, primarily driven by a weak cosmetic ingredients segment. While pharmaceutical and medical lubricant sales showed growth and new distribution agreements offer future potential, the current financial performance and ongoing competitive pressures warrant caution.

Positives

• Pharmaceutical net sales increased by 15% in 2025, recovering from prior manufacturing disruptions.
• Medical lubricant sales increased by 4% in 2025, driven by demand from Chinese customers.
• New distribution agreement with Brenntag Specialties for Natrajel sexual wellness line in key markets (US, Canada, Mexico, France) starting January 2026.
• New marketing strategy for Renacidin led to approval by two major PBMs in February 2026, expected to enhance patient access and commercial growth.
• Achieved 93rd percentile in EcoVadis assessment for Corporate Social Responsibility, indicating strong performance in environmental, labor/human rights, and ethics categories.
• Current ratio improved to 7.3:1 in 2025 from 6.6:1 in 2024, indicating robust short-term liquidity.
• ISO 9001:2015 and EFfCI GMP certifications demonstrate commitment to quality and good manufacturing practices.
• Development of new natural, preservative-free, and non-glycerin products aligns with growing consumer demand for green and sustainable options.

Negatives

• Total sales decreased by 13% in 2025 compared to 2024.
• Net income decreased significantly by 35.2% in 2025.
• Cosmetic ingredient sales, a higher-margin product category, decreased by 45%, primarily due to reduced demand in Asia and overstocking by the largest distributor, ASI.
• Gross profit margin declined to 49% in 2025 from 53% in 2024, reflecting the shift in sales mix and higher per-unit overhead.
• Investment income decreased by 16% due to lower interest rates and less cash from operations.
• Cash generated from operations decreased by 43.3% in 2025.
• Receivables turnover increased from 45 days in 2024 to 52 days in 2025, indicating slower collection of accounts receivable.
• No sales were recorded for the new sexual wellness ingredients line in 2025, despite readiness for manufacturing and distribution.
• The company's Board of Directors elected not to fund a discretionary 401(k) contribution in 2025 due to reduced sales and earnings.

Risks

• Significant pricing pressure from low-cost competitors in the specialty ingredients market, particularly for cosmetic ingredients.
• Potential negative impact on sales volume, prices, and costs due to global supply chain instability, inflation, and changes in U.S. and international trade policies, including tariffs.
• Customer concentration risk, with three pharmaceutical wholesalers and one cosmetic ingredient distributor accounting for approximately 74% of gross sales and 82% of outstanding accounts receivable in 2025.
• Supplier concentration risk, as three major raw material vendors collectively accounted for approximately 82% of raw material purchases in 2025.
• Reliance on a single contract manufacturer for Renacidin; any disruption in their operations could materially impact the company's revenue stream.
• Uncertainty regarding the finalization of a new marketing and distribution agreement with ASI, the largest cosmetic ingredient distributor, with negotiations ongoing since the previous agreement terminated on December 31, 2023.
• The new Medicare Part D Manufacturer Discount Program (MDP) is expected to significantly increase rebate liabilities for drug manufacturers by 2031, despite a temporary reduction for the company as a specified small manufacturer in 2025 and 2026.
• Extended payment terms from a large pharmaceutical distributor contributed to an increase in receivables turnover, potentially impacting cash flow.
• Cybersecurity threats, including data theft or destruction, are ongoing risks, despite implemented controls and regular board oversight.

Future Outlook

Operating expenses are expected to increase modestly in 2026 to support growth initiatives, with R&D expenses also anticipated to rise. The company aims to finalize a new marketing and distribution agreement with ASI in the first half of 2026. Increased formulary coverage for Renacidin is expected to enhance patient access and support long-term commercial growth. Manufacturing and distribution of the new Natrajel sexual wellness line are ready to commence in 2026. The competitive environment in cosmetic ingredients is expected to continue, with plans to enhance competitive position through new product development, especially naturally derived products. While Medicare Part D rebate liabilities are expected to increase significantly by 2031, the company benefits from a reduced phase-in period for 2025 and 2026 due to its small manufacturer designation. Working capital is believed to be sufficient for the next fiscal year, with cash expected to be used for dividends, marketable securities, and growth opportunities.

Management Comments

• "With a refined product portfolio and strategic partnerships, we are well-positioned for future growth, leveraging our expertise in specialty ingredients to capitalize on emerging market opportunities."
• "Our goal is to finalize the contract [with ASI] in the first half of 2026."
• "We believe that increased formulary coverage of Renacidin will enhance patient access and support long-term commercial growth of this product."
• "As the sexual wellness market is an emerging market, especially for new innovative products, we are well positioned to be at the forefront."
• "We expect that this competitive environment will continue in 2026 and we plan to enhance our competitive position by strengthening our core capabilities and investing in new product development, especially in the area of naturally derived products."
• "We expect our research and development expenses in 2026 to be higher than those in 2025 in order to support innovation and growth initiatives."
• "We believe that our working capital is sufficient to support our operating requirements for the next fiscal year."

Industry Context

StockSavvy.ai notes that United-Guardian operates in a dynamic specialty ingredients market, facing intense competition, particularly from lower-cost Asian and European manufacturers in cosmetic ingredients. The company's focus on natural, green, and sustainable products, as evidenced by its COSMOS certification and new product developments, aligns with a significant and growing industry trend driven by consumer demand for environmentally friendly and clean label products. The expansion into sexual wellness ingredients with the Natrajel line positions the company in an emerging market, potentially diversifying its revenue streams. The pharmaceutical segment, particularly with Renacidin, benefits from being the sole FDA-approved drug for its specific purpose, providing a stable, albeit regulated, revenue base. The new Medicare Part D program changes highlight the evolving regulatory landscape impacting pharmaceutical manufacturers' rebate liabilities.

Comparison to Industry Standards

• The company's gross profit margin of 49% in 2025, while a decrease from 53% in 2024, should be benchmarked against specialty chemical and pharmaceutical ingredient manufacturers. For example, larger diversified chemical companies like Ashland Inc. (parent of ASI, a UG distributor) or Croda International Plc (parent of Sederma SAS, another UG distributor) often have varying gross margins across their diverse portfolios, but specialty segments typically aim for higher margins. A 49% margin is generally healthy for a specialty chemical producer, though the decline warrants attention.
• The current ratio of 7.3:1 is exceptionally strong, significantly exceeding typical industry benchmarks for manufacturing companies, which often range from 1.5:1 to 2.5:1. This indicates robust short-term liquidity and financial stability, potentially allowing for strategic investments or acquisitions without external financing.
• The receivables turnover of 52 days (Days Sales Outstanding) is within a reasonable range for B2B sales in specialty chemicals and pharmaceuticals, though the increase from 45 days suggests a slight softening in collection efficiency, possibly due to specific customer payment term changes.
• The company's EcoVadis score in the 93rd percentile places it among industry leaders in corporate social responsibility, a key differentiator in an increasingly sustainability-conscious market, potentially outperforming many smaller and mid-sized competitors who may not have such robust CSR programs.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently ongoing.

Related Party Transactions

• Consulting agreement with Ken Globus (Chairman of the Board, former President) expired May 31, 2024; no payments in 2025 ($20,000 in 2024).
• Payments of $22,438 in 2025 and $23,250 in 2024 to PKF OConnor Davies for accounting and tax services, where Lawrence Maietta (a director) is a senior consultant.

Stakeholder Impact

• Shareholders are impacted by the 35.2% decrease in net income and lower EPS ($0.46 vs $0.71). Dividends were maintained at $0.60/share for the year, but the discretionary 401(k) contribution was not funded due to reduced earnings, which could be a concern. The strong current ratio and sufficient working capital provide financial stability.
• Employees did not receive discretionary 401(k) contributions in 2025 due to reduced sales and earnings. The company maintains a commitment to fair compensation, competitive benefits, and talent development.
• Customers of cosmetic ingredients may experience pricing pressure due to competition. Pharmaceutical customers benefit from increased Renacidin formulary coverage. New sexual wellness products and distribution agreements offer expanded product access.
• Suppliers face concentration risk with three major raw material vendors (82% of purchases) and reliance on one contract manufacturer for Renacidin. The settlement with the Renacidin CM indicates past supply chain issues.
• Creditors face low credit risk due to the company's strong current ratio (7.3:1) and sufficient working capital.

Next Steps

• Finalize the new marketing and distribution agreement with Ashland Specialty Ingredients (ASI) in the first half of 2026.
• Begin manufacturing and distribution of the new Natrajel line of sexual wellness ingredients in 2026.
• Continue to implement the new marketing strategy for Renacidin to leverage PBM formulary approvals and enhance long-term commercial growth.
• Increase research and development expenses modestly in 2026 to support innovation and growth initiatives, particularly in naturally derived products.
• Implement an overarching sustainability procedure including KPIs, review water usage for reduction, and update training programs in leadership, management, and compliance.
• Receive $300,000 worth of Renacidin product at no cost from the contract manufacturer in March 2026 as part of a settlement.
• Board of Directors to meet semi-annually in January and July to discuss dividend declarations.

Key Dates

Recommendation

The filing presents a mixed financial picture. While the significant decline in total sales and net income in 2025 is a negative, driven largely by the underperformance of the cosmetic ingredients segment, there are clear signs of strategic initiatives and growth in other areas. The increase in pharmaceutical and medical lubricant sales, new distribution agreements for the sexual wellness line, and the Renacidin PBM approvals indicate future potential. The company's strong liquidity position (high current ratio) provides a buffer. However, the ongoing competitive pressures, customer/supplier concentration risks, and the delay in finalizing the ASI agreement introduce uncertainty. A "hold" recommendation reflects the balance between current underperformance and future growth catalysts, suggesting investors monitor the execution of new strategies and the resolution of distribution agreements before making further commitments.

Keywords

specialty ingredients, cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness, Renacidin, Lubrajel, Natrajel, SEC filing, 10-K, financial performance, distribution agreements, R&D, corporate governance, sustainability, supply chain, tariffs, Medicare rebates